

# 1           **The effect of influenza virus on the human oropharyngeal microbiome**

2           Elisa Ramos-Sevillano<sup>1</sup>, William G. Wade<sup>2</sup>, Alex Mann<sup>3</sup>, Anthony Gilbert<sup>3</sup>, Robert Lambkin-  
3           Williams<sup>3</sup>, Ben Killingley<sup>4</sup>, Jonathan S. Nguyen-Van-Tam<sup>4</sup>, Christoph M. Tang<sup>1\*</sup>

4

5    Authors' affiliations:

6    <sup>1</sup>Sir William Dunn School of Pathology,  
7    South Parks Road,  
8    University of Oxford,  
9    Oxford OX1 3RE, UK

10

11   <sup>2</sup>Blizard Institute, Barts and The London School of Medicine and Dentistry,  
12   4 Newark Street, London E1 2AT, UK

13

14   <sup>3</sup>hVIVO Services Limited, Queen Mary BioEnterprises Innovation Centre,  
15   42 New Road  
16   London E1 2AX, UK

17

18   <sup>4</sup>Faculty of Medicine & Health Sciences, University of Nottingham,  
19   Hucknall Road  
20   Nottingham NG5 1PB, UK

21

22   \* Corresponding author

23   E-mail:           christoph.tang@path.ox.ac.uk

24   Short title       URT microbiome and influenza

25

26   Key words: microbiome, influenza, upper respiratory tract

27

28

29

30

31

32

33

34

35

36 **Abstract**

37 **Background:** Secondary bacterial infections are an important cause of morbidity and  
38 mortality associated with influenza infection. As bacterial disease can be caused by a  
39 disturbance of the host microbiome, we examined the impact of influenza on the upper  
40 respiratory tract microbiome in a human challenge study.

41 **Methods:** The dynamics and ecology of the throat microbiome were examined following  
42 experimental influenza challenge of 52 previously healthy adult volunteers with Influenza  
43 A/Wisconsin/67/2005 (H3N2) by intranasal inoculation; 35 healthy control subjects were  
44 not subjected to viral challenge. Serial oropharyngeal samples were taken over a 30-day  
45 period, and the V1-V3 region of the bacterial 16S rRNA sequences were amplified and  
46 sequenced to determine the composition of the microbiome. The carriage of pathogens was  
47 also detected.

48 **Results:** forty three of 52 challenged individuals developed proven influenza infection, of  
49 whom 33 became symptomatic. None of the controls developed influenza, although 22%  
50 reported symptoms. The diversity of bacterial communities remained remarkably stable  
51 following the acquisition of influenza, with no significant differences over time between  
52 individuals with influenza and those in the control group. Influenza infection was not  
53 associated with perturbation of the microbiome at the level of phylum or genus. There was  
54 no change in colonisation rates with *Streptococcus pneumoniae* or *Neisseria meningitidis*.

55 **Conclusions:** The throat microbiota is resilient to influenza infection, indicating the  
56 robustness of the upper airway microbiome.

57

58

59 **Introduction**

60 Secondary bacterial infection is a major cause of the mortality and morbidity associated with  
61 influenza virus [1]. Bacterial pneumonia caused millions of deaths during influenza pandemics  
62 in the 20<sup>th</sup> century [2], and remains a frequent complication following non-pandemic  
63 influenza. For example, 94% of a group of patients who died in the 1918 influenza pandemic  
64 demonstrated that all had evidence of secondary bacterial pneumonia [3], while 28% of  
65 fatalities in New York City associated with the 2009 H1N1 influenza pandemic had bacterial  
66 co-infection, with most only diagnosed post-mortem [4].

67

68 Several pathogens cause bacterial infection following influenza. Co-infection with  
69 *Haemophilus influenzae* was so common that it was thought to cause influenza before the  
70 virus was isolated [5]. *Streptococcus pneumoniae* is now the commonest influenza-associated  
71 infection [6]. Cavitary *Staphylococcus aureus* pneumonia is a severe influenza complication,  
72 and secondary pneumonia with MRSA emerged in the 2009 pandemic [7]. There is also an  
73 association between influenza A and systemic *Neisseria meningitidis* infection [8].

74

75 Multiple mechanisms could explain bacterial disease following influenza. The virus is cytolytic  
76 and induces epithelial cell damage, impairment of surfactant production, and reduced muco-  
77 ciliary clearance [9, 10]. Exposure of the epithelial basement membrane and extracellular  
78 matrix can offer binding sites for bacteria expressing matrix binding molecules [11]; glycan  
79 receptors for bacteria can be revealed by the activity of viral and bacterial neuraminidases  
80 (NA) [12, 13]. Additionally increased secretion of galectin 1 and galectin 3 can favour galectin-  
81 mediated adhesion of *S. pneumoniae* and *N. meningitidis* [14]. Murine models indicate that  
82 host cell sialic acid released by NA can also act as a nutrient for pneumococcal growth in the  
83 upper airway, promoting bacterial spread to the lower airways [15].

84

85 The human microbiome is a complex community that has co-evolved with its host. A healthy  
86 microbiota protects against invasion by pathogenic bacteria through a process referred to as  
87 colonisation resistance, in which the microbiota restricts growth or attachment of pathogens  
88 by competing for nutrients and ecological niches, or by direct antagonism [16].

89

90 Several external factors influence the microbiome including age, smoking, and antibiotic  
91 treatment [17-19]. Furthermore changes in the microbiota are found with certain airway  
92 infections [20]. For example, healthy volunteers were reported to have a more diverse  
93 nasopharyngeal microbiome compared with patients suffering from pneumonia [21], while a  
94 highly diverse community is found in patients with asthma, cystic fibrosis, or Chronic  
95 Obstructive Pulmonary Disease [22, 23]. However, little is known about the impact of viral  
96 infection on the microbiota. No specific profile of bacteria in the URT was associated with  
97 seven different viral infections, although an apparent decrease in carriage of *Haemophilus* and  
98 *Neisseria* was observed after rhinovirus infection [24, 25].

99

100 To further understand the cause of secondary bacterial infections, we investigated the impact  
101 of influenza virus on the human nasopharyngeal microbiome. We characterised the  
102 microbiota over a 30- day period in 52 healthy adults challenged with influenza A H3N2, and  
103 32 non-challenged individuals by using barcoded 454 pyrosequencing. This approach allowed  
104 us to define changes in the human microbiome following influenza challenge. Furthermore  
105 we examined whether influenza affected carriage of pathogens resident in the upper airways.

106

107 **MATERIALS AND METHODS**

108 ***Study design***

109 The study took place in a secure quarantine facility with written informed consent from  
110 volunteers, in accordance with the Declaration of Helsinki, and in full compliance with the UK  
111 regulatory and ethical (IRB) requirements.

112

113 Volunteers were screened before study entry to assess susceptibility to the challenge virus.  
114 In brief, volunteers were healthy with no acute or chronic medical condition, between the  
115 ages of 18 and 45, not living with anyone at risk of influenza complications, and not to have  
116 had a seasonal influenza vaccine in the last three years. Blood samples from volunteers were  
117 collected immediately before quarantine entry for antibody testing.

118

119 Subjects were randomly allocated to challenge (n=52) or control groups (n=35) on day -1. On  
120 day 0, individuals in the challenge group were inoculated intranasally with a total of 5.5 log<sub>10</sub>  
121 TCID<sub>50</sub>/ml/nostril of influenza strain A/H3N2/Wisconsin/67/2005. The control group were not  
122 subjected to viral challenge (Figure 1).

123

124 ***Clinical monitoring and sample collection***

125 Volunteers recorded symptoms daily, and vital signs were recorded three times daily.  
126 Nasopharyngeal (NPS) and oropharyngeal swabs, and venous blood were collected on days  
127 -1, 3, 6 and 28. Respiratory specimens were analysed by quantitative PCR and serological  
128 specimens by HAI and microneutralisation (MN) assays. Laboratory confirmed influenza was  
129 defined as: a 4-fold or greater rise in HAI or MN titres between day -2 and day 28, or a positive  
130 NPS test by PCR.

131

132 Volunteers were classified according to their symptoms and signs. 'Influenza-like illness' (ILI)  
133 was defined according to the CDC definition: an illness lasting  $\geq 24$  hours with either a  
134 temperature of  $> 37.9^{\circ}\text{C}$ , or two or more symptoms, at least one of which was respiratory.  
135 Volunteers were 'symptomatic' if they experienced symptoms with no fever, experienced a  
136 single symptom, had  $\geq$  two symptoms but none of which were respiratory, or had an illness  
137 of  $< 24$  hours. Therefore, a volunteer could have an ILI or be Symptomatic, and not be infected  
138 with influenza. Individuals were classified according to their symptomatology and tests into:  
139 ILI<sup>flu+</sup>, subjects who received viral challenge, and had an ILI with evidence of influenza infection  
140 ( $n=19$ ); S<sup>flu+</sup>, subjects who received viral challenge and were symptomatic with evidence of  
141 influenza infection ( $n=14$ ); and ILI/S<sup>flu+</sup> includes individuals belonging to both these groups  
142 ( $n=33$ ). Those not challenged with influenza, who remained asymptomatic/influenza negative  
143 formed the AC (Asymptomatic Control) group ( $n=24$ ).

144

#### 145 ***DNA isolation and pyrosequencing***

146 DNA was extracted from swabs using the MoBio Power Soil isolation kit (MoBio laboratories).  
147 Barcoded primers were used to amplify  $\sim 500$  bp V1-V3 region of the 16S rRNA gene as  
148 previously [26]. Amplification conditions were 5 minutes at  $95^{\circ}\text{C}$ , then 25 cycles of  $95^{\circ}\text{C}$  for  
149 45 seconds,  $53^{\circ}\text{C}$  for 45 seconds,  $72^{\circ}\text{C}$  for 1 minute 30 seconds with a final step of  $72^{\circ}\text{C}$  for 15  
150 minutes. The products were analysed using an Agilent 2100 Bioanalyzer after purification with  
151 the QIAquick kit (Qiagen). Quantitation was performed using Quant-iT Picogreen (Invitrogen).  
152 Samples were pooled at equimolar concentrations, and sequenced using a Roche 454 GS-FLX  
153 Titanium platform.

154

155 ***Sequence analysis***

156 The quality of sequences was assessed using FastQC v0.11.3 (Babraham Institute). Pre-  
157 processing of sequences was performed with mothur v1.35.1 [27] based on the Schloss  
158 operating procedure. Next, trim.flows was used to remove sequences with mismatches in the  
159 primer sequence or the barcode. Sequences were de-noised by shhh.flows, trimmed to  
160 remove primers and barcodes, then aligned to the SILVA 16S rRNA reference alignment using  
161 trim.seqs; chimeric sequences were eliminated by Uchime [28]. Sequences were BLASTed  
162 against the Human Oral Microbiome Database v13.2 at the 98.5% sequence identity level.  
163 Sequences met the following criteria: read length >375 nt. (excluding barcode and primers),  
164 no ambiguous bases, or homopolymers of >8 nt.

165

166 A sequence dissimilarity distance of 0.015 was used to cluster sequences into operational  
167 taxonomic units (OTUs), using the average neighbour algorithm. Taxonomies were assigned  
168 using the HOMD reference dataset. The richness of the microbial communities was calculated  
169 using Chao1 and Catchall indices [29, 30], and diversity estimated with Simpson's inverse [31]  
170 and Shannon [32] indices. Good's non-parametric estimator assessed coverage of  
171 communities in samples [33]. Species diversity between the samples was examined by  
172 analysing the beta diversity. Samples were adjusted to 2997 reads per sample by random  
173 sampling. Distance matrices were generated with the Jaccard Index and thetaYC measure of  
174 dissimilarity [34], and visualized by principal coordinate analysis (PCoA). Dendrograms  
175 representing relationships between samples were analysed by parsimony and UniFrac [35].

176

177

178

179 ***S. pneumoniae and N. meningitidis carriage***

180 *N. meningitidis* was isolated by plating samples to GC selective medium. A 413 bp fragment  
181 encoding the 50S ribosomal protein L6 (RplF) was amplified by PCR, sequenced, and identified  
182 with PubMLST [36]. Meningococcal isolates were characterized by serogrouping, serotyping  
183 and serosubtyping. To detect the pneumococcus, qPCR of a region of *lytA* was performed  
184 using TaqMan (Thermo-Scientific) as previously [37].

185

186 ***Statistical analyses***

187 Analysis of alpha diversity was performed using Kruskal-Wallis test with Dunn's correction for  
188 multiple comparisons was applied. Analysis of Molecular Variance (AMOVA) was used to  
189 evaluate differences between groups in PCoA [38]. Parsimony tests were implemented by  
190 mothur [39]. The Linear Discriminant Analysis (LDA) effect Size (LEfSe) was used to examine  
191 differences in Operational Taxonomic Units (OTUs) in the control/challenged groups [40]; the  
192 alpha values were set to 0.05 and a LDA score of 2.5 was selected. A two-tailed Fisher exact  
193 test was applied to compare colonization rates for pathogens.

194



195 **RESULTS**

196 ***Infection and the development of symptoms after influenza challenge***

197 Although volunteers were screened for antibodies against influenza in advance, three  
198 individuals in the challenge group and three in the control group had serological evidence of  
199 prior H3N2 infection at study entry, so were excluded from subsequent analysis.

200

201 Influenza infection was confirmed in 43 of the 52 individuals (82%) who subjected to influenza  
202 challenge; 33 subjects developed symptoms including 19 with ILI (ILI<sup>flu+</sup>). An additional three  
203 subjects were challenged with influenza and became symptomatic, but no evidence of  
204 influenza infection. Three other challenged individuals remained asymptomatic with no  
205 evidence of influenza.

206

207 ***Characterisation of the pharyngeal microbiome***

208 A total of 2,505,196 sequences were obtained from 87 individuals (52 in the challenged group,  
209 and 35 controls) at four time points: day -1, 3, 6 and 28. DNA extraction failed for one sample,  
210 and amplification was unsuccessful from four samples, giving a total of 343 samples. Chimeric  
211 sequences were removed by alignment to the SILVA database, resulting in 2,057,548  
212 sequences.

213

214 Initially we compared individuals who were symptomatic or had ILI with proven influenza  
215 infection from the challenged group (n=33) with asymptomatic individuals from the control  
216 group (n=24). To normalize the dataset, we took 2997 sequences from each sample; 11  
217 samples had fewer than 2997 sequences so were excluded, leaving a total of 213 samples.  
218 2209 OTUs (based on <98.5% of identity, > 4 representatives) were identified, with 24% of

219 sequences falling into only three OTUs: OTU1 (accounting for 9.78% of sequences), with  
220 predominant members *Fusobacterium periodonticum*, and OTU2 and OTU3 (7.8% and 7%,  
221 respectively), with the predominant members of both unclassified streptococci; OTU2 and  
222 OTU3 were identified as *S. salivarius/S. vestibularis*, and *S. mitis/S. pneumoniae*, respectively.

223

#### 224 ***Changes in the diversity of nasopharynx microbiota based on OTU analysis***

225 The coverage of bacterial communities was high (mean 97.6%  $\pm$  0.007%), with samples having  
226 an average of 161 OTUs (range 63 to 321). The mean number of OTUs at each time point was  
227 not significantly different between the groups (asymptomatic controls vs. ILI/S<sup>flu+</sup>  $p$  0.4425,  
228 Figure 2A). Furthermore, the number of OTUs remained remarkably constant over time, even  
229 in the ILI<sup>flu+</sup> and S<sup>flu+</sup> groups, with no significant difference compared with Asymptomatic  
230 controls (Supplementary Figures 1 and 2,  $p$  = 0.5543 and 0.5836, respectively). The Chao 1  
231 index measures the predicted total richness of the community so gives a higher value (median  
232 of 262 OTUs, range 84 to 577 OTUs, Figure 2B) than the number of recorded OTUs; the non-  
233 parametric estimator Catchall gave a median value of 437 OTUs per sample (range 66 to  
234 2643). Using these estimators, there were no significant differences in the richness of the  
235 between the ILI/S<sup>flu+</sup> group and Asymptomatic control groups (Figure 2B). Furthermore, there  
236 was no significant difference in the richness of microbial communities in symptomatic  
237 individuals even when we compared individuals in the ILI/S<sup>flu+</sup> group with asymptomatic  
238 controls (Supplementary Figures 1 and 2).

239

240 We also estimated the diversity of bacterial communities using the Shannon index. Again no  
241 difference was detected between the challenged and control groups (Figure 2C,

242 Supplementary Figure 1 and 2), even when we analysed the diversity of the communities in  
243 highly symptomatic ILI subjects and the Asymptomatic controls (Supplementary Table 1).

244

245 Next, we used beta diversity analysis to assess differences between samples. Dendrograms  
246 were generated highlighting similarities of the membership and structure of bacterial  
247 communities using Jaccard and thetaYC indices, respectively. At the four time points, results  
248 for certain individuals cluster together (*e.g.* individual  $S^{\text{flu}+}$  individual 2,  $ILI^{\text{flu}+6}$ ,  $S^{\text{flu}+7}$ ,  $S^{\text{flu}+10}$ ,  
249  $ILI^{\text{flu}+11}$ ,  $S^{\text{flu}+12}$ ,  $ILI^{\text{flu}+13}$ ,  $S^{\text{flu}+17}$ ,  $ILI^{\text{flu}+28}$ , AC61, AC65), indicating that the individual had a  
250 stronger influence on microbiome than influenza. This was evidenced by samples from four  
251 different time points clustering together in the dendrogram (Supplementary Figure [43](#)). No  
252 significant clustering of OTUs in the control or the influenza challenged groups, or over time  
253 was found when we applied a parsimony test. The thetaYC index, which considers the  
254 structure of communities by looking at the relative abundance of OTUs, yielded a complex  
255 dendrogram (Supplementary Figure [53](#)). Although there were no large shifts in the  
256 communities, minor changes were detected when we applied a parsimony test with the  
257 clustering in the ILI/ $S^{\text{flu}+}$  and Asymptomatic control groups slightly different on days 3, 6 and  
258 28 ( $p < 0.02$ ,  $p < 0.024$ , and  $p < 0.001$ , respectively). However these differences were not found  
259 after applying a Unifrac unweighted test.

260

261 The community structure and membership of the oropharyngeal microbiota was visualized  
262 by PCoA (Figure 3). Small differences were found in the structure but not membership of  
263 communities in the ILI/ $S^{\text{flu}+}$  group and Asymptomatic controls at day 3 and day 6 ( $p < 0.035$   
264 and  $p < 0.033$ , respectively, Figure 3). This difference was also found when we compared  $S^{\text{flu}+}$   
265 individuals with Asymptomatic controls ( $p < 0.001$ ). The structure was also visualized for each

266 group separately (Supplementary Figure 3), where we found that day 6 post infection showed  
267 statistically significant difference compared to baseline within the ILI/S<sup>flu+</sup> group (  $p < 0.036$ ),  
268 while in the Asymptomatic control group, days 3, 6 and 28 showed some statistically  
269 significant difference compared to baseline ( $p < 0.001$ ), indicating that the process of being in  
270 quarantine might have subtle effects on the URT microbiome.

271 LEfSe analysis found that the abundance of some OTUs in these groups was significantly  
272 different on days 3 and day 6 post-infection (Figure 4). OTUs which are more abundant within  
273 the ILI/S<sup>flu+</sup> group at day 3 included OTU11 (*Prevotella melaninogenica*), OTU14 (*Leptotrichia*),  
274 OTU38 (Human Oral Taxon 352) and OTU38 (*Porphyromonas*), while OTU42 (*Burkholderiales*)  
275 and OTU6 (*Leptotrichia* HOT218) were more abundant within Asymptomatic control group. At  
276 day 6 OTU18 (*Fusobacterium necrophorum*) and OTU37 (*Prevotella*) were significantly more  
277 abundant in individuals in the ILI/S<sup>flu+</sup> group.

278

### 279 ***Alteration in the ecology of the pharyngeal microbiome during influenza***

280 Next we examined the communities by phylum. Of 2,057,548 sequences, 19,416 could not be  
281 classified, while the remainder were distributed into 11 phyla, with 97% of them belonging to  
282 five phyla, *Actinobacteria* (7.9%), *Fusobacteria* (24.2%), *Firmicutes* (36.5%), *Bacteroidetes*  
283 (14.1%) and *Proteobacteria* (14.4%). We also detected *Spirochaetes*, *Synergistetes*,  
284 *Tenericutes* and GN02 together with members of two uncultured prokaryotes, TM7 and SR1,  
285 at < 1% of the total microbiota.

286

287 The abundance of each phylum remained remarkably constant following influenza challenge  
288 with similar patterns seen across both groups. There was a significant change in the  
289 *Bacteroidetes* which increased in the ILI/S<sup>flu+</sup> group at day 3 post-infection compared to

290 Asymptomatic controls (Figure 5B). We also analysed how these phyla change over the time.  
291 Within the ILI/S<sup>flu+</sup> group there was a significant change in the abundance of *Actinobacteria*  
292 which increased by day 6 post infection compared to baseline ( $p < 0.01$ ), and returned to basal  
293 levels by day 28 (~~Supplementary~~ Figure 6A5).

294 *Firmicutes* were also increased between day 6 and 28 post infection in the control group  
295 (Supplementary Figure 6C), with an increase in *Streptococcus* (Supplementary Figure 7A),  
296 coinciding with individuals returning to the community so this might reflect changes in social  
297 behaviour.

298

299 With regard to the composition at the genus level, *Streptococcus* was a core component of  
300 the microbiome, accounting for 21.8% of all bacteria, with *Fusobacterium* and *Prevotella* also  
301 abundant (comprising 15.4% and 9.9%, respectively). *Neisseria*, *Haemophilus* and  
302 *Campylobacter* each accounted for 2-5% of the microbiota (~~Figure 6~~). Differences were  
303 identified between the ILI/S<sup>flu+</sup> group and Asymptomatic controls (Figure 7E), with a significant  
304 increase in relative abundance of *Prevotella* at day 3 and 28 post infection in the challenged  
305 group ( $p < 0.05$ ), and in *Fusobacterium* by day 28 post infection ( $p < 0.05$ ) (Figure 7C and 7B).

306 Within the ILI/S<sup>flu+</sup> group, a minor increase in *Actinomyces* was observed at day 6 post infection  
307 ( $p < 0.05$ ) and in parallel *Haemophilus* decreased ( $p < 0.01$ ) (~~Supplementary~~ Figure 8I and 8E6E  
308 and 6I).

309

### 310 ***S. pneumoniae* and *N. meningitidis* carriage is unaltered during influenza**

311 As 16S sequencing often cannot discriminate different species, we analysed carriage of two  
312 important respiratory pathogens, *S. pneumoniae* and *N. meningitidis*. The rate of colonization  
313 by encapsulated or non-encapsulated *N. meningitidis* was similar with no difference between

314 challenged and controls individuals (Figure [97](#)). For *S. pneumoniae* 16 of 36 influenza  
315 challenged subjects (31%) and 12 of 23 controls (34%) were positive for *S. pneumoniae* using  
316 qPCR at day 3 (Fisher's exact test  $p = 0.8163$ ).

317 **DISCUSSION**

318 We performed the first prospective characterization of bacterial communities within the  
319 human URT during influenza infection. Previous studies have examined changes in the  
320 microbiota following challenge with other viruses [24, 25], and found only minor changes in  
321 the abundance of certain bacterial genera. Furthermore, cross-sectional studies have  
322 characterized the microbiome of patients with influenza [41]. However we are not aware of  
323 previous studies that have examined individuals following a defined influenza challenge.

324

325 We detected only slight perturbations in the upper respiratory microbiota following challenge  
326 with influenza A. There was a high level of inter-individual variation in the upper respiratory  
327 microbiome, a common feature of studies on humans [26], and found that the microbiota  
328 contains at least 11 different phyla, with five phyla (*Actinobacteria*, *Firmicutes*, *Fusobacteria*,  
329 *Bacteroidetes* and *Proteobacteria*) constituting the core microbiome, similar to other studies  
330 [25]. Additionally *Fusobacteria* were highly prevalent (accounting for 24.2% of all OTUs), in  
331 agreement with previous work [19].

332

333 The microbiota were dominated by *Streptococcus* and *Fusobacterium*, which include species  
334 that can cause influenza-associated pulmonary disease. However during the acquisition of  
335 influenza, the profile of the URT microbiome remained remarkably stable. Although we  
336 detected no large shift in the bacterial population at the genus level, there was a significant  
337 increase in the abundance of *Prevotella* in the ILI/S<sup>flu+</sup> group at days 3 and 28, a key time when  
338 secondary bacterial infection occurs; although *P. melaninogenica* was associated with this  
339 increase at day 3, little is known about its role in respiratory disease.

340

341 Overall, our study does not provide evidence that influenza infection has a marked impact in  
342 shaping the pharyngeal microbiome. However, certain factors might be responsible for the  
343 lack of effect we observed. Participants were healthy adults, who do not generally suffer  
344 secondary bacterial infection; studies in at-risk individuals might reveal more significant  
345 changes in the microbiome, although pose a serious ethical and safety dilemma. In addition,  
346 effects might have become evident using a larger study population. Furthermore, 16S rRNA-  
347 based methods are limited and lack species-level resolution for particular genera, including  
348 *Streptococcus* and *Neisseria*. Even though cohort studies have established a relationship  
349 between influenza and the rate of pneumococcal carriage, we did not find any difference in  
350 pneumococcal carriage following influenza infection. For the meningococcus, we also  
351 examined capsule expression, as this virulence factor is only expressed by a sub-set of strains  
352 [42]. However, there was no alteration in the rate of carriage of either encapsulated or non-  
353 encapsulated *N. meningitidis* in our cohort with the advent of influenza infection. We did not  
354 examine swabs for the presence of *S. aureus*, as this is a far less frequent secondary bacteria  
355 pathogen following influenza than *S. pneumoniae*, and is associated with severe disease, and  
356 not milder forms of infection such as represented by this challenge model.

357

358 In conclusion, our findings demonstrate that the upper airway microbiota is not  
359 reprogrammed by acquisition of influenza, with only minor perturbations seen in bacterial  
360 communities. Further studies are required to examine the cross-kingdom interactions that are  
361 responsible for secondary bacterial infection being a key player in the mortality and morbidity  
362 associated with influenza.

363

364



365 **Acknowledgments**

366 Work in CMTs laboratory is supported by an award from the Wellcome Trust. The quarantine  
367 challenge study was supported by a Cooperative Grant from US Centers for Disease Control  
368 and Prevention, # 1U01P000497-01. JSN-V-T is currently on secondment to the Department  
369 of Health, England. The views expressed in this manuscript are not necessarily those of the  
370 Department of Health, England.

371

372

373

374

375 **References**

- 376 1. Smith AM, & McCullers, J.A. Secondary Bacterial Infections in Influenza Virus Infection  
377 Pathogenesis. *Influenza Pathogenesis and Control - Volume I*. Volume 385 of the series *Current*  
378 *Topics in Microbiology and Immunology* 2014. p. 327-56.
- 379 2. Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. *The*  
380 *Journal of infectious diseases*. 2007;195(7):1018-28. doi: 10.1086/511989. PubMed PMID:  
381 17330793.
- 382 3. Sheng ZM, Chertow DS, Ambroggio X, McCall S, Przygodzki RM, Cunningham RE, et al.  
383 Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. *Proceedings*  
384 *of the National Academy of Sciences of the United States of America*. 2011;108(39):16416-21. doi:  
385 10.1073/pnas.1111179108. PubMed PMID: 21930918; PubMed Central PMCID: PMC3182717.
- 386 4. Lee EH, Wu C, Lee EU, Stoute A, Hanson H, Cook HA, et al. Fatalities associated with the 2009  
387 H1N1 influenza A virus in New York city. *Clinical infectious diseases : an official publication of the*  
388 *Infectious Diseases Society of America*. 2010;50(11):1498-504. doi: 10.1086/652446. PubMed PMID:  
389 20420514.
- 390 5. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. *Lancet*.  
391 1933;2:66-8. PubMed PMID: WOS:000188727300024.
- 392 6. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. *Clin*  
393 *Microbiol Rev*. 2006;19(3):571-82. doi: 10.1128/CMR.00058-05. PubMed PMID: 16847087; PubMed  
394 Central PMCID: PMC1539103.
- 395 7. Murray RJ, Robinson JO, White JN, Hughes F, Coombs GW, Pearson JC, et al. Community-  
396 Acquired Pneumonia Due to Pandemic A(H1N1)2009 Influenzavirus and Methicillin Resistant  
397 *Staphylococcus aureus* Co-Infection. *Plos One*. 2010;5(1). doi: ARTN e8705  
398 10.1371/journal.pone.0008705. PubMed PMID: WOS:000273714600008.
- 399 8. Cartwright KA, Jones DM, Smith AJ, Stuart JM, Kaczmarek EB, Palmer SR. Influenza A and  
400 meningococcal disease. *Lancet*. 1991;338(8766):554-7. PubMed PMID: 1678811.
- 401 9. Bakaletz LO. Viral potentiation of bacterial superinfection of the respiratory tract. *Trends in*  
402 *microbiology*. 1995;3(3):110-4. PubMed PMID: 7773588.
- 403 10. Murphy TF, Bakaletz LO, Smeesters PR. Microbial interactions in the respiratory tract. *The*  
404 *Pediatric infectious disease journal*. 2009;28(10 Suppl):S121-6. doi: 10.1097/INF.0b013e3181b6d7ec.  
405 PubMed PMID: 19918134.
- 406 11. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. *Nature*  
407 *reviews Microbiology*. 2014;12(4):252-62. doi: 10.1038/nrmicro3231. PubMed PMID: 24590244.
- 408 12. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary  
409 bacterial pneumonia. *The Journal of infectious diseases*. 2005;192(2):249-57. doi: 10.1086/430954.  
410 PubMed PMID: 15962219; PubMed Central PMCID: PMC2715995.
- 411 13. Shakhnovich EA, King SJ, Weiser JN. Neuraminidase expressed by *Streptococcus pneumoniae*  
412 desialylates the lipopolysaccharide of *Neisseria meningitidis* and *Haemophilus influenzae*: a  
413 paradigm for interbacterial competition among pathogens of the human respiratory tract. *Infection*  
414 *and immunity*. 2002;70(12):7161-4. PubMed PMID: 12438402; PubMed Central PMCID: PMC133026.
- 415 14. Nita-Lazar M, Banerjee A, Feng C, Amin MN, Frieman MB, Chen WH, et al. Desialylation of  
416 airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin  
417 binding. *Molecular immunology*. 2015;65(1):1-16. doi: 10.1016/j.molimm.2014.12.010. PubMed  
418 PMID: 25597246; PubMed Central PMCID: PMC4344939.
- 419 15. Siegel SJ, Roche AM, Weiser JN. Influenza Promotes Pneumococcal Growth during  
420 Coinfection by Providing Host Sialylated Substrates as a Nutrient Source. *Cell Host Microbe*.  
421 2014;16(1):55-67. doi: 10.1016/j.chom.2014.06.005. PubMed PMID: WOS:000341142600009.
- 422 16. Faust K, Raes J. Microbial interactions: from networks to models. *Nature reviews*  
423 *Microbiology*. 2012;10(8):538-50. doi: 10.1038/nrmicro2832. PubMed PMID: 22796884.

- 424 17. Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, et al. Disordered microbial  
425 communities in the upper respiratory tract of cigarette smokers. *PloS one*. 2010;5(12):e15216. doi:  
426 10.1371/journal.pone.0015216. PubMed PMID: 21188149; PubMed Central PMCID: PMC3004851.
- 427 18. Biesbroek G, Wang X, Keijser BJ, Eijkemans RM, Trzcinski K, Rots NY, et al. Seven-valent  
428 pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. *Emerging*  
429 *infectious diseases*. 2014;20(2):201-10. doi: 10.3201/eid2002.131220. PubMed PMID: 24447437;  
430 PubMed Central PMCID: PMC3901477.
- 431 19. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-  
432 term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome.  
433 *PloS one*. 2010;5(3):e9836. doi: 10.1371/journal.pone.0009836. PubMed PMID: 20352091; PubMed  
434 Central PMCID: PMC2844414.
- 435 20. Huang YJ, Lynch SV, Wiener-Kronish JP. From microbe to microbiota: considering microbial  
436 community composition in infections and airway diseases. *American journal of respiratory and*  
437 *critical care medicine*. 2012;185(7):691-2. doi: 10.1164/rccm.201111-2030ED. PubMed PMID:  
438 22467799.
- 439 21. de Steenhuijsen Piters WA, Huijskens EG, Wyllie AL, Biesbroek G, van den Bergh MR,  
440 Veenhoven RH, et al. Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients.  
441 *The ISME journal*. 2015. doi: 10.1038/ismej.2015.99. PubMed PMID: 26151645.
- 442 22. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, et al. Decade-long  
443 bacterial community dynamics in cystic fibrosis airways. *Proceedings of the National Academy of*  
444 *Sciences of the United States of America*. 2012;109(15):5809-14. doi: 10.1073/pnas.1120577109.  
445 PubMed PMID: 22451929; PubMed Central PMCID: PMC3326496.
- 446 23. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway microbiome dynamics  
447 in exacerbations of chronic obstructive pulmonary disease. *Journal of clinical microbiology*.  
448 2014;52(8):2813-23. doi: 10.1128/JCM.00035-14. PubMed PMID: 24850358; PubMed Central  
449 PMCID: PMC4136157.
- 450 24. Yi H, Yong D, Lee K, Cho YJ, Chun J. Profiling bacterial community in upper respiratory tracts.  
451 *BMC infectious diseases*. 2014;14:583. doi: 10.1186/s12879-014-0583-3. PubMed PMID: 25391813;  
452 PubMed Central PMCID: PMC4236460.
- 453 25. Allen EK, Koepfel AF, Hendley JO, Turner SD, Winther B, Sale MM. Characterization of the  
454 nasopharyngeal microbiota in health and during rhinovirus challenge. *Microbiome*. 2014;2:22. doi:  
455 10.1186/2049-2618-2-22. PubMed PMID: 25028608; PubMed Central PMCID: PMC4098959.
- 456 26. Kistler JO, Booth V, Bradshaw DJ, Wade WG. Bacterial community development in  
457 experimental gingivitis. *PloS one*. 2013;8(8):e71227. doi: 10.1371/journal.pone.0071227. PubMed  
458 PMID: 23967169; PubMed Central PMCID: PMC3743832.
- 459 27. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing  
460 mothur: open-source, platform-independent, community-supported software for describing and  
461 comparing microbial communities. *Applied and environmental microbiology*. 2009;75(23):7537-41.  
462 doi: 10.1128/AEM.01541-09. PubMed PMID: 19801464; PubMed Central PMCID: PMC2786419.
- 463 28. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed  
464 of chimera detection. *Bioinformatics*. 2011;27(16):2194-200. doi: 10.1093/bioinformatics/btr381.  
465 PubMed PMID: 21700674; PubMed Central PMCID: PMC3150044.
- 466 29. Chao A. Nonparametric-Estimation of the Number of Classes in a Population. *Scand J Stat*.  
467 1984;11(4):265-70. PubMed PMID: WOS:A1984AJZ6300006.
- 468 30. Bunge J. Estimating the number of species with CatchAll. *Pacific Symposium on*  
469 *Biocomputing Pacific Symposium on Biocomputing*. 2011:121-30. PubMed PMID: 21121040.
- 470 31. Simpson EH. Measurement of diversity. *Nature*. 1949;163:688-. doi: 10.1038/163688a0.
- 471 32. Shannon CE. A mathematical theory of communication. *The bell system technical journal*.  
472 1948;27:379-423, 623-56
- 473 33. Good IJ. The Population Frequencies of Species and the Estimation of Population  
474 Parameters. *Biometrika*. 1953;40(3/4):237-64.

- 475 34. Yue JC, Clayton MK. A similarity measure based on species proportions. *Commun Stat-Theor*  
476 *M.* 2005;34(11):2123-31. doi: Doi 10.1080/Sta-200066418. PubMed PMID: WOS:000233019600005.
- 477 35. Lozupone CA, Knight R. Species divergence and the measurement of microbial diversity.  
478 *FEMS microbiology reviews.* 2008;32(4):557-78. doi: 10.1111/j.1574-6976.2008.00111.x. PubMed  
479 PMID: 18435746; PubMed Central PMCID: PMC2443784.
- 480 36. Bennett JS, Watkins ER, Jolley KA, Harrison OB, Maiden MC. Identifying *Neisseria* species by  
481 use of the 50S ribosomal protein L6 (rplF) gene. *Journal of clinical microbiology.* 2014;52(5):1375-81.  
482 doi: 10.1128/JCM.03529-13. PubMed PMID: 24523465; PubMed Central PMCID: PMC3993661.
- 483 37. Carvalho Mda G, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, et al.  
484 Evaluation and improvement of real-time PCR assays targeting *lytA*, *ply*, and *psaA* genes for  
485 detection of pneumococcal DNA. *Journal of clinical microbiology.* 2007;45(8):2460-6. doi:  
486 10.1128/JCM.02498-06. PubMed PMID: 17537936; PubMed Central PMCID: PMC1951257.
- 487 38. Excoffier L, Smouse PE, Quattro JM. Analysis of molecular variance inferred from metric  
488 distances among DNA haplotypes: application to human mitochondrial DNA restriction data.  
489 *Genetics.* 1992;131(2):479-91. PubMed PMID: 1644282; PubMed Central PMCID: PMC1205020.
- 490 39. Slatkin M, Maddison WP. Detecting isolation by distance using phylogenies of genes.  
491 *Genetics.* 1990;126(1):249-60. PubMed PMID: 2227384; PubMed Central PMCID: PMC1204129.
- 492 40. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic  
493 biomarker discovery and explanation. *Genome biology.* 2011;12(6):R60. doi: 10.1186/gb-2011-12-6-  
494 r60. PubMed PMID: 21702898; PubMed Central PMCID: PMC3218848.
- 495 41. Chaban B, Albert A, Links MG, Gardy J, Tang P, Hill JE. Characterization of the upper  
496 respiratory tract microbiomes of patients with pandemic H1N1 influenza. *PloS one.*  
497 2013;8(7):e69559. doi: 10.1371/journal.pone.0069559. PubMed PMID: 23844261; PubMed Central  
498 PMCID: PMC3699515.
- 499 42. Kugelberg E, Gollan B, Farrance C, Bratcher H, Lucidarme J, Ibarz-Pavon AB, et al. The  
500 Influence of IS 1301 in the Capsule Biosynthesis Locus on Meningococcal Carriage and Disease. *Plos*  
501 *One.* 2010;5(2). doi: ARTN e9413  
502 10.1371/journal.pone.0009413. PubMed PMID: WOS:000274924300005.

503

504

505

506 **FIGURE LEGENDS**

507

508 **Figure 1. Study timeline.**

509 Volunteers were screened prior to admission to a quarantine unit on the day before receiving  
510 an intranasal challenge of Influenza A (on day 0), then followed for 28 days. The volunteers  
511 were kept in quarantine for six days post inoculation. Controls were screened and housed in  
512 identical conditions, but were not subjected to viral challenge. Throat swabs were collected  
513 at different time points during the study (*i.e.* on days -1, 3, 6 and 28 post-inoculation).

514

515 **Figure 2. Analysis of the richness of the URT microbiome.**

516 The diversity of the microbiome was analysed by sequencing the V1-3 region of 16SrRNA  
517 amplified from samples obtained from the ILI/S<sup>flu+</sup> (white boxes) and Asymptomatic control  
518 (grey boxes) groups following influenza A challenge. The box whisker plots extend from 25<sup>th</sup>  
519 to 75<sup>th</sup> percentiles, and the ends of the whiskers show the maximum and minimum values.  
520 The line in the middle of the box represents the median and the dots represent the outliers  
521 1.5 greater or lower than the interquartile distance. Analysis was based on: (A) the number of  
522 OTUs; (B) Chao1 index; and (C) Shannon diversity index at baseline, 3 (3dpi), 6 (6dpi) and 28  
523 (28dpi) days post influenza challenge.

524

525 **Figure 3. Throat microbiota structure in ILI/S<sup>flu+</sup> and Asymptomatic control groups during**  
526 **influenza challenge.** PCoA based on the Thetayc index comparing community structure of  
527 samples from ILI/S<sup>flu+</sup> infected group (blue open circles) and Asymptomatic control (red open  
528 circles) groups at days 3 (A), and day 6 (B). The centroid represents the arithmetic mean for

529 each of the groups and each dot represents the microbiota structure profile for each of the  
530 samples, while the ellipses represent the 95% of the samples belonging to each group.

531

532 **Figure 4. LEfSe analysis of abundant OTUs in ILI/S<sup>flu+</sup> and Asymptomatic controls.**

533 The positive scale indicates the LDA score (Log10) for the most abundant taxa in the ILI/S<sup>flu+</sup>  
534 group (green bars), while the negative scale represents LDA scores for prevalent taxa in the  
535 Asymptomatic control group on days 3 (A) and 6 (B).

536

537 **Figure 5. Relative abundance of common phyla in the human oropharynx.**

538 Comparison of the abundance of each phylum between individuals (open squares) in the  
539 ILI/S<sup>flu+</sup> group (+), and the Asymptomatic controls (-). The phyla are indicated in each panel.

540 Error bars represent the standard deviation error of the mean (SDSEM). Non-parametric  
541 Kruskal-Wallis test for multiple comparisons was applied to identify statistically significant  
542 differences in relative abundance between groups: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ . Samples are from  
543 individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge, or not  
544 (in the control group).

545

546 **Figure 6. Relative abundance of common phyla in the human oropharynx.**

547 The abundance of each phylum in individuals within the ILI/S<sup>flu+</sup> group (+). The phyla are  
548 indicated in each panel. Error bars represent the standard deviation (SD). Non-parametric  
549 Kruskal-Wallis test for multiple comparisons was applied to identify statistically significant  
550 differences in relative abundance between groups: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ . Samples are from  
551 individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge.

552

553

554 **Figure 76. Relative abundance of the common genera in the human oropharynx.**

555 Comparison of the abundance of each phylum in individuals (open squares) between the  
556 ILI/S<sup>flu+</sup> group (+), and the Asymptomatic controls (-). Genera are indicated in each  
557 panel. Error bars represent the standard deviation (SDSEM). Non-parametric  
558 Kruskal-Wallis test for multiple comparisons was applied to identify statistically significant  
559 differences in relative abundance between groups: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ . Samples are from  
560 individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge, or not  
561 (in the control group).

562

563 **Figure 8. Relative abundance of the common genera in the human oropharynx.**

564 The abundance of each genera in individuals within the ILI/S<sup>flu+</sup> group (+). The genera are  
565 indicated in each panel. Error bars represent the standard deviation (SD). Non-parametric  
566 Kruskal-Wallis test for multiple comparisons was applied to identify statistically significant  
567 differences in relative abundance between groups: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ . Samples are from  
568 individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge.

569

570

571

572 **Figure 97. *N. meningitidis* carriage following influenza challenge.**

573 Meningococcal carriage in the ILI/S<sup>flu+</sup> group (A) and in the Asymptomatic control group (B) at  
574 different times following challenge. Carriage of non-groupable *N. meningitidis* was unchanged  
575 during influenza, and ranged between 11.4 and 13.5 % except for controls from day 6 and 28.

576 There was no change in the carriage of groupable *N. meningitidis* over time or between  
577 groups.

578

579

580



581 **SUPPORTING INFORMATION**

582

583 **Supplementary Figure 1. Richness measurements of the ILI<sup>flu+</sup> and Asymptomatic control**  
584 **groups following influenza A challenge.**

585 The box whisker plots extend from 25<sup>th</sup> to 75<sup>th</sup> percentiles and the ends of the whiskers show  
586 the maximum and minimum values. The line in the middle of the box represents the median  
587 and the dots represent the outliers being 1.5 greater or lower than the interquartile distance.  
588 (A) Number of OTUs, (B) Chao1 index and (C) the Shannon diversity index at baseline (B), and  
589 3 (3dpi), 6 (6dpi), and 28 (28dpi) days after the influenza challenge.

590

591 **Supplementary Figure 2. Richness measurements of the S<sup>flu+</sup> and Asymptomatic control**  
592 **groups following influenza challenge.**

593 The box whisker plots extend from the 25<sup>th</sup> to 75<sup>th</sup> percentiles and the ends of the whiskers  
594 show the maximum and minimum values. The line in the middle of the box represents the  
595 median and the dots represent the outliers, 1.5 greater or lower than the interquartile  
596 distance. (A) Number of OTUs, (B) Chao1 index, and (C) the Shannon diversity index at baseline  
597 (B), 3 (3dpi), 6 (6dpi) and 28 (28dpi) days after the influenza challenge.

598

599 **Supplementary Figure 3. Throat microbiota structure in ILI/S<sup>flu+</sup> and Asymptomatic control**  
600 **groups during influenza challenge. PCoA based on the Thetayc index comparing community**  
601 **structure of samples within ILI/S<sup>flu+</sup> infected group (A) and Asymptomatic control (B) groups**  
602 **at Baseline (purple), day 3 (green) day 6 (blue) and day 28 after challenge (red). Each dot**  
603 **represents the microbiota structure profile for each of the samples, while the ellipses**  
604 **represent the 95% of the samples belonging to each group.**

605

606

607

608 **Supplementary Figure 43. Dendrograms of throat communities in ILI/S<sup>flu+</sup> and**  
609 **Asymptomatic control groups during an influenza challenge.**

610 Clustering of throat samples at different time points of an influenza challenge compared  
611 based on their community membership by using classical Jaccard Index. AC = Asymptomatic  
612 Control, ILI<sup>flu+</sup> = subjects who received viral challenge and had an ILI with evidence of influenza  
613 infection, S<sup>flu+</sup> = subjects who received viral challenge and were Symptomatic with evidence  
614 of influenza infection, B = baseline, 3dpi = 3 days post infection, 6dpi = 6 days post infection,  
615 28dpi = 28 days post infection. Numbers indicate subject or patient number.

616

617 **Supplementary Figure 54. Dendrograms of throat communities in ILI/S<sup>flu+</sup> and**  
618 **Asymptomatic control groups during an influenza challenge.**

619 ~~(A)~~ Clustering of throat samples at different time points of an influenza challenge compared  
620 based on their community structure by using classical Thetayc. AC = Asymptomatic Control,  
621 ILI<sup>flu+</sup> = subjects who received viral challenge and had an ILI with evidence of influenza  
622 infection, S<sup>flu+</sup> = subjects who received viral challenge and were Symptomatic with evidence  
623 of influenza infection, B = baseline, 3dpi = 3 days post infection, 6dpi = 6 days post infection,  
624 28dpi = 28 days post infection. Numbers indicate subject or patient number.

625

626 **Supplementary Figure 65. Relative abundance of common phyla in the human oropharynx.**

627 The abundance of each phylum in individuals within the Asymptomatic controlILI/S<sup>flu+</sup> group  
628 over time. The phyla are indicated in each panel. Error bars represent the standard deviation  
629 (SD). Non-parametric Kruskal-Wallis test for multiple comparisons with a Dunn's post test  
630 ~~correction~~correction was applied to identify statistically significant differences in relative  
631 abundance between groups: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ , \*\*\*;  $p < 0.001$ . Samples are from  
632 individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge.

633

634 **Supplementary Figure 76. Relative abundance of the common genera in the human**  
635 **oropharynx.**

636

637 The abundance of each phylum in individuals within the Asymptomatic controlILI/S<sup>flu+</sup> group  
638 over time. The genera are indicated in each panel. Error bars represent the standard deviation  
639 (SD). Non-parametric Kruskal-Wallis test with a Dunn's post test correction was applied to  
640 identify statistically significant differences in relative abundance between groups: \*,  $p < 0.05$ ;  
641 \*\*,  $p < 0.01$ , \*\*\*;  $p < 0.001$ . Samples are from individuals prior on entry to quarantine  
642 (baseline), and days 3, 6 and 28 after challenge.

643

644

645 ~~Supplementary Figure 7. Throat microbiota structure in ILI/S<sup>flu+</sup> and control groups during~~  
646 ~~influenza challenge. PCoA based on the Thetayc index comparing community structure of~~  
647 ~~samples within ILI/S<sup>flu+</sup> infected group (A) and Asymptomatic control (B) groups at Baseline~~  
648 ~~(purple), day 3 (green) day 6 (blue) and day 28 after challenge (red). Each dot represents the~~  
649 ~~microbiota structure profile for each of the samples, while the ellipses represent the 95% of~~  
650 ~~the samples belonging to each group.~~

651

652 **Supplementary Table 1. Alpha diversity of ILI/S<sup>flu+</sup> and control groups.**